Skip to content

Geron GERN Change in AP

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Incyte logo
IncyteINCY
$23.45M+1,186%
Immunome logo
ImmunomeIMNM
$1.42M+137%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$5.74M-263%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$3M-200%
Celcuity logo
CelcuityCELC
$4.08M+566%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's change in AP?
Geron (GERN) reported change in AP of $1.46M in Q1 2026.
How has Geron's change in AP changed year-over-year?
Geron's change in AP increased by 359.9% year-over-year, from -$563K to $1.46M.
What is the long-term trend for Geron's change in AP?
Over 3 years (2021 to 2024), Geron's change in AP has grown at a 118.9% compound annual growth rate (CAGR), from -$232K to $2.44M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.